Date: 2017-03-14
Type of
information: Results
phase: preclinical
Announcement:
Company: Quantum Genomics (France)
Product: QGC001
Action
mechanism:
- enzyme inhibitor/Brain Aminopeptidase A inhibitor (BAPAI). QGC001 is a Brain Aminopeptidase A inhibitor (BAPAI) product. This candidate is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain. Several preclinical studies and two clinical studies have been conducted already using QGC001 to assess its pharmacokinetic, pharmacodynamic, safety and tolerance parameters in animals and humans.
Disease:
Therapeutic
area: Cardiovascular diseases
Country:
Trial
details:
Latest
news:
- • On March 14, 2017, Quantum Genomics announces positive data from new preclinical studies with QGC001. Results from these preclinical studies, conducted using FDA-recommended tests on murine models, confirmed QGC001 did not induce damage to the chromosomes or the mitotic apparatus of rat bone marrow cells after orally administering doses of up to 2000 mg/kg/day, which are expected to exceed a therapeutically relevant dose.
- Additionally, QGC001 was determined to be nonphototoxic
in the in vitro neutral red uptake phototoxicity test using the murine Balb/c 3T3 cell line recommended by the FDA.
- Quantum Genomics remains on track to submit in the coming months an Investigational New Drug (IND) application to initiate a phase II clinical study in targeted population of hypertensive patients in the United States.
Is
general: Yes
